Phase 1 Trial Begins Dosing Patients With Investigational Brain-penetrant HER2 Inhibitor

Phase 1 Trial Begins Dosing Patients With Investigational Brain-penetrant HER2 Inhibitor
Patient dosing has begun in Zion Pharma's Phase 1 clinical trial in the United States to evaluate the safety of its investigational HER2 inhibitor, ZN-A-1041, in people with HER2-positive breast cancer and other solid tumors. "We are excited to have initiated our Phase 1 trial for ZN-A-1041," Zack Cheng, PhD, chairman, CEO, and co-founder of Zion Pharma, said in a press release. HER2 (human epidermal growth factor receptor 2) is a protein that promotes the growth of some cancers, including about 20% of breast cancers. When a cancer's growth is driven by HER2, that cancer is said to be HER2-positive. Medications that inhibit the activity of this protein — which ZN-A-1041 is designed to do — can slow or stop the growth of HER2-positive tumors. While approved targeted therapies can inhibit HER2 for breast cancer, ZN-A-1041 is being developed to fulfil a specific unmet medical need concerning the brain. Tumors that grow in one part of the body can spread to another part of the body in a process called metastastis. Sometimes, tumors will metastasize to the brain, causing a major health concern. Tu
Subscribe or to access all post and page content.